Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) EBITDA: 2023-2025

Historic EBITDA for Camp4 Therapeutics (CAMP) over the last 2 years, with Sep 2025 value amounting to -$15.1 million.

  • Camp4 Therapeutics' EBITDA fell 11.98% to -$15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.4 million, marking a year-over-year decrease of 3.68%. This contributed to the annual value of -$51.8 million for FY2024, which is 5.07% down from last year.
  • Per Camp4 Therapeutics' latest filing, its EBITDA stood at -$15.1 million for Q3 2025, which was down 19.96% from -$12.6 million recorded in Q2 2025.
  • Over the past 5 years, Camp4 Therapeutics' EBITDA peaked at -$11.7 million during Q3 2023, and registered a low of -$15.1 million during Q3 2025.
  • In the last 3 years, Camp4 Therapeutics' EBITDA had a median value of -$12.6 million in 2025 and averaged -$13.0 million.
  • As far as peak fluctuations go, Camp4 Therapeutics' EBITDA decreased by 15.29% in 2024, and later rose by 0.15% in 2025.
  • Quarterly analysis of 3 years shows Camp4 Therapeutics' EBITDA stood at -$13.0 million in 2023, then fell by 2.22% to -$13.3 million in 2024, then fell by 11.98% to -$15.1 million in 2025.
  • Its last three reported values are -$15.1 million in Q3 2025, -$12.6 million for Q2 2025, and -$12.4 million during Q1 2025.